The INHALE-3 trial (2024) compared the efficacy of an inhaled insulin regimen (Afrezza) plus long acting degludec insulin against usual care over 17 weeks among 123 adults. More participants using the ...
Apart from Victoza, which was approved for Type 2 diabetes in 2010, liraglutide also underpins Novo’s older weight loss drug Saxenda and its insulin-degludec-based diabetes combination therapy ...
A recent study published in the journal Diabetes Care found that the combination of Technosphere insulin (TI) plus insulin degludec is non-inferior to the usual care of an automated insulin delivery ...
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy TA117 24 January 2007 24 January 2007 Methadone and buprenorphine ...
MONDAY, Dec. 16, 2024 (HealthDay News) -- For adults with type 1 diabetes, a regimen of inhaled Technosphere insulin (TI) plus insulin degludec is noninferior to usual care for glycemic control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback